Osteopontin as a potential diagnostic biomarker for ovarian cancer.

@article{Kim2002OsteopontinAA,
  title={Osteopontin as a potential diagnostic biomarker for ovarian cancer.},
  author={Jae-Hoon Kim and S. Skates and T. Uede and K. Wong and J. Schorge and C. Feltmate and R. Berkowitz and D. Cramer and S. Mok},
  journal={JAMA},
  year={2002},
  volume={287 13},
  pages={
          1671-9
        }
}
CONTEXT Development of new biomarkers for ovarian cancer is needed for early detection and disease monitoring. Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cancer cells, whose products may then be further validated as potential biomarkers. OBJECTIVE To describe validation studies of an up-regulated gene known as osteopontin, previously identified using a cDNA microarray system. DESIGN, SETTING, AND PARTICIPANTS Experimental and… Expand
Osteopontin as an Adjunct to CA 125 in Detecting Recurrent Ovarian Cancer
Purpose: CA125 is currently the only tumor marker to have a validated role in the postoperative monitoring of ovarian cancer. Osteopontin (OPN) is a putative plasma biomarker that was recentlyExpand
Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
TLDR
Although inferior to CA125 in predicting clinical response to therapy, OPN rose earlier in 90% of the patients developing recurrent disease and the quadratic functional trends of OPN and CA125 were each highly significant (P < 0.0001). Expand
Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.
TLDR
It is demonstrated that serum osteopontin concentrations in post-oophorectomy patients with recurrent ovarian cancer are not greater than in healthy controls, and within this heterogeneous patient population, the values do correlate with bulk of disease. Expand
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature
TLDR
Proteomic approaches are experimental technologies applied to ovarian and other cancers that have promise for early diagnosis and in advancing treatment directions and are the first step in fulfilling the promise of personalized molecular medicine. Expand
Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.
TLDR
Microarray technology offered a method to identify tumor biomarkers with potential clinical usefulness and indicated that CKB gene expression is up-regulated in ovarian cancer cells in vitro and in vivo and that C KB enzyme activity is significantly elevated in sera from ovarian cancer patients, including those with stage I disease. Expand
Clinical significance of osteopontin expression in cervical cancer
PurposeNew diagnostic markers, other than squamous cell carcinoma (SCC) antigen, are needed for the detection of cervical cancer. Osteopontin (OPN) is a candidate frequently associated with severalExpand
VSGP/F-Spondin: A New Ovarian Cancer Marker
The discovery of genes that are overexpressed in ovarian cancers provides valuable insight into ovarian cancer biology and will lead to the development of more effective treatment strategies forExpand
Emerging role of inhibin as a biomarker for ovarian cancer.
TLDR
A test for serum inhibin has been developed which is able to diagnose granulosa cell tumors and mucinous carcinomas with high accuracy and when used in conjunction with the CA125 test, the two tests detect the majority of ovarian cancers with high sensitivity and specificity. Expand
Emerging Role of Inhibin as a Biomarker for Ovarian Cancer
Ovarian cancer is the most lethal gynecological malignancy as it is diagnosed at a late clinical stage in more than 80% of patients. The development of diagnostic tests that can detect all types ofExpand
Serum protein markers for early detection of ovarian cancer.
  • G. Mor, I. Visintin, +6 authors D. Ward
  • Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2005
TLDR
A blood test, based on the simultaneous quantization of four analytes (leptin, prolactin, osteopontin, and insulin-like growth factor-II), that can discriminate between disease-free and EOC patients, including patients diagnosed with stage I and II disease, with high efficiency is reported. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
TLDR
Prostasin is overexpressed in epithelial ovarian cancer and should be investigated further as a screening or tumor marker, alone and in combination with CA 125. Expand
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
TLDR
Findings suggest plasma LPA levels may represent a potential biomarker for ovarian cancer and other gynecologic cancers, however, these findings are preliminary and require confirmation in larger studies. Expand
Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.
  • L. Luo, D. Katsaros, +5 authors E. Diamandis
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
TLDR
High concentration hK10 was found to be associated with advanced disease stage, serous histological type, suboptimal debulking, and large residual tumor (>1 cm; all P < 0.05). Expand
Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray
TLDR
The assembly and use of a 1877-member microarray representing cDNA clones from a range of prostate cancer stages and grades, precursor lesions and normal tissue is described, and analysis of expression patterns identified many up-regulated transcripts. Expand
Delineation of prognostic biomarkers in prostate cancer
TLDR
Two genes—hepsin, a transmembrane serine protease, and pim-1, a serine/threonine kinase—are assessed at the protein level using tissue microarrays consisting of over 700 clinically stratified prostate-cancer specimens and linked clinical and pathology data are established. Expand
ras mutation and expression of the ras‐regulated genes osteopontin and cathepsin L in human esophageal cancer
TLDR
The ras‐regulated gene osteopontin was over‐expressed in 100% of squamous‐cell carcinomas and in 58% of adenocarcinomas relative to matched normal esophageal mucosa, and patterns of immunoreactivity for osteoponin protein also varied betweenSquamous‐ cell carcinomas (tumor cell staining) and adenOCarc inomas (predominantly tumor‐infiltrating macrophages). Expand
Osteopontin: possible role in prostate cancer progression.
  • G. Thalmann, R. Sikes, +6 authors L. Chung
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
TLDR
Findings taken together suggest that OPN may act as a paracrine and autocrine mediator of prostate cancer growth and progression. Expand
Osteopontin expression in a group of lymph node negative breast cancer patients
TLDR
The results of this pilot study suggest that the ability of breast cancer cells to either synthesize OPN or to bind and sequester OPN from the microenvironment may be associated with tumor aggressiveness and poor prognosis. Expand
Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP).
TLDR
expression of OPN primarily by ovarian neoplasms with favorable prognosis is an intriguing new finding of potential importance in the pathogenesis of ovarian LMPs. Expand
Differential osteopontin expression in lung cancer.
TLDR
Results suggest that OPN is mainly expressed in NSCLC, especially among SCC, and its concomitant induction with Ras activation may play a crucial role in the development of SCC. Expand
...
1
2
3
4
5
...